Star Combo Pharma Limited Overview
Star Combo Pharma is a Sydney-based, founder-controlled micro-cap that manufactures vitamins, dietary supplements, powders, gummies and skincare products in TGA-licensed facilities at Smithfield, New South Wales. Since FY2022 it has refocused from an Australia-to-China retail and cross-border e-commerce model toward contract (OEM) manufacturing for third-party health brands, supplemented by a small portfolio of proprietary brands — Living Healthy, Costar, Amax and J&K — sold through Terry White Chemmart in Australia and distributors in Vietnam and China. The legacy Austoyou e-commerce business, 49% sold in November 2022, ceased trading in October 2025. The company carries a net-cash balance sheet (c. A$18m of cash and term deposits against a market value below A$20m) and pays a small fully franked dividend. Its investment case now hinges on replacing a lost major OEM contract and filling recently commissioned capacity, against a background of thin margins and high customer concentration.
Company's own description. The latest annual reporting describes the group's principal activity as the manufacture and distribution of health food products and nutritional supplements, and states that the strategic focus is to become a leading Australian contract manufacturer for the vitamin and health-supplement sector. The two reported operating segments are (i) the Star Combo / OEM Division — development, manufacturing, marketing and sale of natural health supplements and skincare products — and (ii) the Austoyou retail business, an Australia-to-China e-commerce platform (described variously as offering 700 or 5,000+ product lines) plus, historically, Koala Mall retail stores in Sydney (FY2025 4E, Note 3; 1H FY2026 4D, Note 2).
Independent characterisation. In economic substance Star Combo is now a single-site, small-scale complementary-medicines contract manufacturer. Roughly three-quarters of revenue comes from manufacturing bulk and finished product to the specifications of third-party brand owners (OEM), with the balance from its own brands and "other" manufacturing sales. The retail segment, once a third of revenue, had shrunk to about 3% of sales by 1H FY2026 and stopped trading in October 2025. The business is therefore exposed primarily to (a) the order books of a small number of Australian supplement brands, (b) Australian pharmacy-channel demand for its own Living Healthy range, and (c) export demand into Vietnam and China.
Business and revenue model.
The model is 100% product-based: there is no service, subscription or licensing revenue disclosed. Formulation and R&D support are bundled into OEM pricing rather than billed separately (not separately disclosed).
Value-chain position. Star Combo sits in the midstream of the complementary-medicines value chain: it buys raw materials (materials were A$17.15m, or 80% of FY2025 cost of sales), formulates, encapsulates/tablets/blends, packs and ships to brand owners, distributors and pharmacy chains. It does not own significant retail distribution in Australia; the downstream brand owner captures most of the consumer margin. Its own brands give it a modest foothold further down the chain.
Customer types. Australian and international supplement brand owners (OEM clients, including a "leading Australian health supplement brand" that placed a A$5.0m order in FY2022 and Chemist Warehouse, which had a A$1.5m order book in October 2021); pharmacy groups (Terry White Chemmart); overseas distributors (Happy Services Co. Ltd in Vietnam); and, historically, Chinese consumers via Austoyou (Q2 FY22 Business Update; FY2023 AR).
End-markets served. Australian vitamins and dietary supplements; Asian export markets for "Australian-made" complementary medicines (Vietnam, China); natural skincare; and, since a FY2023 APVMA licence, pet supplements.
Strategy
Stated strategy (themes from FY2023–FY2026 reporting).
-
Become a leading Australian contract manufacturer for the vitamin and health-supplement sector — repeated verbatim in every directors' report since FY2022.
-
Grow OEM client base by targeting established brands currently supplied by alternative manufacturers (FY2025 4E).
-
Expand capacity and capability — powder line (FY2023), gummy line (TGA licence FY2023), pet supplements (APVMA licence FY2023), intermittent 24-hour shifts, and "commissioning additional manufacturing capacity at Smithfield" (1H FY2026 outlook).
-
Strengthen own-brand distribution domestically (Terry White Chemmart) and in Asia (Vietnam via Happy Services; targeting the ageing population and rising middle class) with an intention to secure longer-term distribution arrangements (FY2025 4E).
-
Exit non-core retail — 49% Austoyou sale (Nov 2022), Koala Mall closure, Austoyou cessation (Oct 2025).
-
Shareholder returns — fully franked dividend policy introduced FY2024 at c. 50% of PBT; A$500k paid in each of October 2024 and October 2025, and c. A$405k declared for FY2026 (A$0.003/share).
Initiatives in the last 24 months (Oct 2024 – Oct 2026):
Not disclosed: No formal transformation or cost programme with targets, no ESG commitments, no investor-day materials, and no medium-term financial targets or numerical guidance have been published. Management's outlook statements are qualitative (e.g., "positive" outlook in FY2024; capacity commissioning in FY2026).
Products & Services
The company does not publish an itemised SKU catalogue or price list in its ASX filings; the portfolio below is reconstructed from annual reports, announcements and data-provider descriptions. Pricing is not publicly disclosed for any line.
OEM / Contract Manufacturing (Star Combo / Costar Pharma Laboratory)
| Offering | Description / capability | Target customer | Launch / latest milestone | Source |
|---|---|---|---|---|
| Hard-capsule encapsulation (bulk) | High-volume bulk capsule manufacture; FY2022 orders of c. 290m and 120m capsules; capsule output up 71% in Q3 FY2022 | Australian supplement brand owners, pharmacy retailers | Core since TGA licensing (c. 2009+) | Q2 FY22 update; Inside FMCG |
| Tablets | Tablet manufacturing under TGA GMP (implied by founder's capsule/tablet background and listed medicine production) | Brand owners | Not specifically dated | Directors' Report |
| Powder production and packaging line | Powder blending and packing (incl. milk-powder style products); line ready July 2022; substantially damaged by October 2022 fire and partly rebuilt | Brand owners, export customers | Jul 2022 | FY2023 AR Note 13 |
| Gummy vitamins | New gummy production facility; TGA licence received; supply targeted from 2H CY2024 | Brand owners targeting the Australasian gummy segment | Licence FY2023 | FY2023 Chairman's Letter |
| Pet supplements | APVMA licence to manufacture pet supplements | Animal-health brand owners | FY2023 | FY2023 Chairman's Letter |
| Product formulation and development | Formulation of new products for clients — e.g., "Sleep Diet" sleep/weight-management product formulated for Bio-E (2019) | Brand owners and new-brand entrants | Ongoing | Pharmacy Daily 2019 |
| Quality assurance services | QA and compliance under TGA licence (listed as a service line by data providers) | OEM clients | Ongoing | MarketScreener profile |
Own Brands
| Brand | Description | Channel / customer | Notes | Source |
|---|---|---|---|---|
| Living Healthy | Vitamins and supplements; brand carried as an indefinite-life intangible (A$667,591) based on its product registrations | Sold in Australia exclusively through Terry White Chemmart's nominated distributor (c. 450 stores per InvestSMART profile); also placed in China (2019) | Only intangible still carried; no impairment indicators at 30 June 2025 | FY2025 4E Notes 1(H), 4, 14 |
| Costar | Proprietary health supplement range (named after Costar Pharma Laboratory) | Vietnam via Happy Services Co. Ltd; Australia | Vietnam distributor exceeded targets in FY2022–FY2023 | FY2023 AR; Inside FMCG |
| Amax | Proprietary health supplement range | Australia/overseas distributors | Product specifics not disclosed | FY2025 4E |
| J&K | Proprietary health supplement range | Australia/overseas distributors | Product specifics not disclosed | FY2025 4E |
| Skincare | Face masks, moisturising creams, serums, concentrates and oils (data-provider description); hyaluronic-acid expertise from founder | Retail/export | Product-level detail not disclosed | Morningstar profile |
Retail (discontinued)
| Offering | Description | Status | Source |
|---|---|---|---|
| Austoyou | Australia-to-China cross-border e-commerce platform selling Australian health products (700–5,000+ lines depending on filing) | 49% sold Nov 2022; ceased trading Oct 2025; brand, platform, customer-relationship and licence intangibles fully impaired | 1H FY2026 4D; FY2025 Note 14 |
| Koala Mall | Sydney retail stores serving tourists/daigou (two stores at peak, incl. Ashfield) | Closed (last store closed FY2023) | FY2023 AR |
Financial Narrative
Sources: FY2022–FY2023 from FY2023 Annual Report; FY2024–FY2025 from FY2025 Appendix 4E/Financial Report; FY2026 from TipRanks/Yahoo Finance aggregation of the FY2026 Appendix 4E. Derived ratios are analyst calculations.
Income statement: notes and sources
Notes: (1) The company's statements label EPS as "cents" but present dollar values (e.g., "0.03" for FY2025); the table converts to cents using NPAT and the weighted share count (135.08m; 134.58m in FY2022). (2) FY2025 Note 9 reconciles EPS to a net profit of A$3,981,283, which conflicts with the A$5,248,658 on the face of the income statement — an internal inconsistency in the filing. (3) Aggregator gross profit differs from filing-derived gross profit for FY2022–FY2024 (TipRanks: 5.61, 4.66, 5.44), likely due to classification of depreciation; filing-derived values are shown. (4) Aggregator EBITDA for FY2025 (A$6.99m) is below an analyst build of EBIT plus D&A (c. A$7.4m); aggregator values are shown for consistency with FY2026. (5) FY2026 EPS and DPS derived from NPAT of A$394.61k and the A$0.003 final dividend.
Margins and growth
FY2022 growth uses the TipRanks FY2021 revenue of A$26.72m as the base. Revenue CAGR FY2022–FY2026: 0.7%; FY2022–FY2025: 6.7%.
Commentary. The five-year record divides into three phases. FY2022–FY2023 was a transition: retail revenue collapsed with Chinese border closures and the end of tourist/daigou demand, while OEM revenue grew 28–30% a year; reported losses were driven by non-cash write-downs (Austoyou goodwill/intangibles in FY2022, fire-destroyed plant in FY2023). FY2024–FY2025 was the high-water mark of the OEM strategy: record output, gross margin expansion from 17.9% to 22.6% as the low-margin retail mix fell away and fixed costs were spread over higher volumes, and a clean underlying PBT of A$1.9m in FY2025. FY2025 statutory profit (A$5.25m) is, however, dominated by the A$5.0m insurance settlement; on the company's own reconciliation, underlying PBT was A$1.94m. FY2026 marks an inflection downward: revenue fell 15% to A$23.6m on the loss of a major OEM client and the retail shutdown, gross margin slipped to 21.2%, and NPAT fell to c. A$0.39m — with the second half roughly breakeven (1H NPAT was A$0.41m, implying a small 2H loss), consistent with the aggregator's note that FY2026 operating profit was slightly negative.
Balance sheet
At 31 December 2025 (1H FY2026 4D): cash A$4.07m, term deposits A$14.10m, inventories A$3.73m, PP&E A$18.01m, total assets A$46.99m, total liabilities A$8.30m, lease liabilities A$4.25m (re-measured upward), working capital A$20.82m, attributable equity A$38.54m.
Commentary. The balance sheet is the company's principal strength. Borrowings are negligible (vehicle and ERP finance loans of under A$0.1m); the only material "debt" is a related-party lease over the Smithfield site owned by the founder's company, Antoine International Pty Ltd (A$3.87m at 30 June 2025). Cash and deposits nearly equal half of equity and comfortably exceed the market capitalisation. Accumulated losses (A$5.3m at 30 June 2025) and a A$25.5m negative group-reorganisation reserve reflect the pre-IPO common-control restructuring and historic write-downs. Land at 165 Woodpark Road is carried at a 2023 valuation of A$6.05m (cost A$3.9m), and leasehold improvements of A$8.9m sit on the related-party site — an asset that would ultimately accrue to the landlord.
Cash flow
FY2026 capex derived as OCF less aggregator FCF. FY2022 OCF per filing is A$0.53m (aggregator shows A$0.09m). In FY2022, 106,880 dollars of shares were cancelled in connection with a reduction in Austoyou deferred consideration — a non-cash adjustment, not a buyback.
Commentary. FY2025 operating cash flow (A$11.9m) was inflated by the A$5.0m insurance receipt and a A$4.6m working-capital release (receivables down A$2.1m, inventories down A$1.4m, payables up A$1.1m). FY2026 OCF of A$3.3m is respectable relative to NPAT because of depreciation (c. A$0.8m in 1H alone) and continued inventory reduction; 1H FY2026 OCF was only A$0.58m, as payables unwound by A$2.3m. Capex has stepped back up (c. A$2.5m in FY2026) as "additional manufacturing capacity at Smithfield" was commissioned (1H FY2026 outlook statement).
Ratios
ROIC applies a 25% notional tax rate; FY2022 asset turnover uses closing assets. FY2025 ROE/ROA/ROIC are flattered by the insurance gain; on underlying PBT (A$1.94m taxed at 25%) ROE would be c. 4.1%. Net debt/EBITDA is negative because the company is net cash.
Ratio commentary. Returns on capital have never been strong on an underlying basis: even in the best clean year (FY2025), underlying ROE was low-single-digit, because a large, under-utilised asset base (A$18–20m of PP&E plus A$18m of cash) supports only c. A$25m of manufacturing revenue at a 7% underlying pre-tax margin. Working-capital discipline improved sharply in FY2025 (CCC down from 125 to 47 days), helped by the timing of a large customer's receipts. The decline in asset turnover to 0.48x in FY2026 captures the core problem: revenue fell while the asset base kept growing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 22.88 | 24.70 | 26.02 | 27.81 | 23.57 |
Cost of sales (AUD Mn) | 18.79 | 19.91 | 20.30 | 21.54 | — |
Gross profit (AUD Mn) | 4.09 | 4.79 | 5.71 | 6.27 | 4.99 |
Other income incl. interest (AUD Mn) | 1.03 | 0.29 | 0.46 | 5.67 | — |
Asset impairment / write-off (AUD Mn) | 1.46 | 4.41 | 0.00 | 0.88 | — |
EBIT — PBT plus finance costs (AUD Mn) | -0.91 | -3.27 | 1.20 | 5.50 | — |
EBITDA — aggregator (AUD Mn) | -0.13 | -2.53 | 2.24 | 6.99 | 1.24 |
Profit before tax (AUD Mn) | -1.08 | -3.45 | 1.00 | 5.31 | — |
Adjusted PBT excl. fire/impairment and insurance (AUD Mn) | 0.38 | 0.96 | 1.00 | 1.94 | — |
Income tax benefit/(expense) (AUD Mn) | 0.39 | -0.55 | -0.25 | -0.06 | — |
Net profit after tax (AUD Mn) | -0.70 | -4.00 | 0.75 | 5.25 | 0.39 |
NPAT attributable to members (AUD Mn) | -0.70 | -4.00 | 0.73 | 5.25 | — |
Basic EPS (A cents) | -0.52 | -2.96 | 0.54 | 3.89 | 0.29 |
Diluted EPS (A cents) | -0.52 | -2.96 | 0.54 | 3.89 | 0.29 |
Dividend per share declared for year (A cents) | 0.00 | 0.00 | 0.37 | 0.37 | 0.30 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | -14.4 | 8.0 | 5.3 | 6.9 | -15.2 |
Gross margin (%) | 17.9 | 19.4 | 22.0 | 22.6 | 21.2 |
EBIT margin (%) | -4.0 | -13.2 | 4.6 | 19.8 | — |
EBITDA margin (%) | -0.6 | -10.2 | 8.6 | 25.1 | 5.3 |
Adjusted PBT margin (%) | 1.7 | 3.9 | 3.8 | 7.0 | — |
Net margin (%) | -3.0 | -16.2 | 2.9 | 18.9 | 1.7 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 43.44 | 42.23 | 42.82 | 48.45 | 50.11 |
Cash and cash equivalents (AUD Mn) | 4.39 | 2.99 | 2.16 | 3.59 | — |
Term deposits >3 months (AUD Mn) | 6.00 | 6.50 | 5.20 | 14.52 | — |
Cash plus term deposits (AUD Mn) | 10.39 | 9.49 | 7.36 | 18.11 | 18.01 |
Trade and other receivables (AUD Mn) | 3.18 | 4.30 | 4.48 | 2.38 | — |
Inventories (AUD Mn) | 5.37 | 4.20 | 6.34 | 4.97 | — |
Property, plant and equipment (AUD Mn) | 19.10 | 19.05 | 19.68 | 18.44 | — |
Goodwill and intangibles (AUD Mn) | 0.70 | 0.69 | 0.68 | 0.67 | — |
Borrowings — current (AUD Mn) | 0.04 | 0.04 | 0.01 | 0.02 | — |
Borrowings — non-current (AUD Mn) | 0.08 | 0.01 | 0.00 | 0.04 | — |
Lease liabilities — total (AUD Mn) | 4.01 | 4.15 | 4.02 | 3.87 | — |
Total debt incl. leases (AUD Mn) | 4.12 | 4.19 | 4.03 | 3.93 | 4.19 |
Net debt (negative = net cash) (AUD Mn) | -6.27 | -5.30 | -3.33 | -14.18 | -13.82 |
Total liabilities (AUD Mn) | 8.04 | 8.97 | 9.30 | 10.19 | 11.28 |
Equity attributable to members (AUD Mn) | 35.41 | 33.09 | 33.32 | 38.08 | 38.83 |
Working capital — current assets less current liabilities (AUD Mn) | 15.07 | 13.77 | 13.48 | 19.93 | — |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | 0.53 | 1.88 | -0.32 | 11.94 | 3.28 |
Capital expenditure (AUD Mn) | 7.29 | 2.73 | 1.44 | 0.39 | 2.46 |
Free cash flow (AUD Mn) | -6.76 | -0.85 | -1.76 | 11.55 | 0.82 |
Investing cash flow incl. term deposits (AUD Mn) | -3.24 | -3.23 | -0.14 | -9.72 | -2.02 |
Dividends paid (AUD Mn) | 0.00 | 0.00 | 0.00 | 0.50 | 0.50 |
Share buybacks (AUD Mn) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financing cash flow (AUD Mn) | -0.17 | -0.05 | -0.37 | -0.80 | -0.94 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE — NPAT / average equity (%) | -1.9 | -11.7 | 2.2 | 14.7 | 1.0 |
ROA — NPAT / average assets (%) | -1.6 | -9.3 | 1.8 | 11.5 | 0.8 |
ROIC — after-tax EBIT / (equity + debt − cash) (%) | -2.7 | -11.4 | 3.6 | 17.1 | — |
Current ratio (x) | 4.76 | 4.18 | 3.77 | 4.40 | — |
Debt / equity incl. leases (x) | 0.12 | 0.13 | 0.12 | 0.10 | 0.11 |
Net debt / EBITDA (x) | — | — | -1.49 | -2.03 | -11.15 |
Interest coverage — EBIT / finance costs (x) | -5.3 | -17.5 | 6.1 | 28.7 | — |
Asset turnover — revenue / average assets (x) | 0.53 | 0.58 | 0.61 | 0.61 | 0.48 |
Days sales outstanding — trade receivables (days) | 35 | 59 | 62 | 30 | — |
Days inventory outstanding (days) | 104 | 77 | 114 | 84 | — |
Days payables outstanding — trade payables (days) | 45 | 45 | 51 | 67 | — |
Cash conversion cycle (days) | 94 | 91 | 125 | 47 | — |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Australia — total (AUD Mn) | 16.67 | 20.48 | 24.81 | 26.37 |
China — total (AUD Mn) | 6.21 | 4.22 | 1.21 | 1.45 |
Group revenue (AUD Mn) | 22.88 | 24.70 | 26.02 | 27.81 |
Revenue by Region by Segment-Region
| Segment-Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Star Combo — Australia (AUD Mn) | 15.71 | 20.34 | 22.15 | 24.38 |
Star Combo — China (AUD Mn) | 0.49 | 0.42 | 1.21 | 1.45 |
Austoyou — Australia (AUD Mn) | 0.96 | 0.15 | 2.66 | 1.99 |
Austoyou — China (AUD Mn) | 5.72 | 3.80 | 0.00 | 0.00 |
Geographic Revenue
| Region | FY2023 growth (%) | FY2024 growth (%) | FY2025 growth (%) |
|---|---|---|---|
Australia | 22.9 | 21.1 | 6.3 |
China | -32.0 | -71.4 | 20.2 |
Point Details
| Point | Price (AUD) | Source |
|---|---|---|
IPO issue price (May 2018) | 0.50 | InvestSMART |
First-day close (16 May 2018) | 0.79 | InvestSMART |
All-time high | 2.03 | InvestSMART |
52-week range (as of mid-2026) | 0.11 – 0.28 | Google Finance |
Pre-1H FY2026 result (Feb 2026) | 0.205 | InvestSMART |
Post-result (22 Jun 2026) | 0.115 | InvestSMART |
Aug 2026 | 0.13 | Motley Fool |
18 Sep 2026 (implied) | c. 0.14 | Yahoo Finance (A$18.9m mkt cap) |
Valuation Multiples
| Multiple | FY2025 basis | FY2026 basis |
|---|---|---|
P/E (x) | 3.6 (statutory, incl. insurance gain) | c. 48 |
EV (AUD Mn) = market cap − cash/deposits + debt incl. leases | — | c. 5.1 |
EV/EBITDA (x) | 0.7 | c. 4.1 |
EV/Sales (x) | 0.18 | c. 0.22 |
P/B (x) | 0.50 | c. 0.49 |
Dividend yield (%) | — | c. 2.1 (A$0.003 / A$0.14) |
Amount/share by Year
| Year | Amount/share (AUD) | Franking | Ex-date | Paid | Total (AUD) |
|---|---|---|---|---|---|
FY2024 final | 0.0037 | 100% | 14 Oct 2024 | 31 Oct 2024 | 500,000 |
FY2025 final | 0.0037 | 100% | 14 Oct 2025 | 31 Oct 2025 | 500,000 |
FY2026 final | 0.003 | 100% | 13 Oct 2026 | 30 Oct 2026 | c. 405,000 |
Obligation Details
| Obligation | ≤6 months | 6–12 months | 1–3 years | >3 years | Total |
|---|---|---|---|---|---|
Trade payables | 5,173,507 | 0 | 0 | 0 | 5,173,507 |
Borrowings (vehicle finance) | 12,241 | 12,241 | 35,429 | 0 | 59,911 |
Leases (Smithfield) | 82,596 | 82,596 | 388,725 | 3,317,416 | 3,871,333 |
Analyst Conclusions
Management guidance. No numerical guidance is provided. The most recent outlook statement (1H FY2026) says the FY2026 strategy remains focused on growing contract manufacturing and commissioning additional Smithfield capacity. FY2026 outlook commentary from the Appendix 4E was not available for review.
Consensus expectations. None (no broker coverage).
Bull case
-
Asset backing with optionality: At c. A$0.14 the stock trades at roughly half of NTA (A$0.28) and below its cash and deposits (c. A$0.13/share), implying an enterprise value of only c. A$5m for a licensed manufacturing business that generated A$1.9m underlying PBT as recently as FY2025.
-
Proven ability to win OEM volume: OEM/own-brand revenue grew at a 17% CAGR from FY2022 to FY2025; with new capacity commissioned, replacing the lost contract would restore revenue toward A$27–28m and margins toward FY2025 levels.
-
Strategic value in a consolidating sector: Foreign buyers have paid substantial prices for Australian TGA-licensed capacity (Probiotec EV c. A$325m), and Vietnam's rising share of Australian supplement exports supports Asian strategic interest.
Bear case
-
Earnings have reset to breakeven: FY2026 NPAT of c. A$0.39m (with a 2H loss) includes meaningful interest income on A$14m of deposits; underlying manufacturing profit may be close to zero.
-
Concentration and scale disadvantage: A single contract loss removed c. 18% of half-year revenue, showing dependence on a few clients in a market where larger, foreign-backed rivals hold scale advantages.
-
Governance and capital-allocation discount is structural: A founder-controlled register (≥36.7% insiders), a minority-independent board, a related-party site lease, reporting inconsistencies and a history of value-destructive deals (Austoyou write-offs; aborted Bio-E) suggest the NTA discount may persist.
Catalysts and monitorables (next 12 months):
-
FY2026 Annual Report (c. 23 Oct 2026): segment split, FY2026 outlook, top-20 shareholder list, remuneration.
-
2026 AGM (expected Nov 2026): commentary on new OEM wins and capacity utilisation.
-
1H FY2027 Appendix 4D (expected late Feb 2027): evidence of OEM revenue recovery.
-
Outcome of the outstanding product/general liability claim.
-
Any capital-management decision on the A$14m of deposits (special dividend, buyback, acquisition, or construction at 165 Woodpark Road).
-
Changes in the Terry White Chemmart arrangement or Vietnam distribution.
-
Any corporate approach given the discount to NTA.
Analyst verdict.
Star Combo Pharma is, at its core, a small, founder-run contract manufacturer whose strategic pivot from China retail to Australian OEM manufacturing was successful through FY2025 but has proven fragile. The FY2025 result, which looked like a breakout, was flattered by a A$5.0m insurance settlement; the company's own reconciliation put underlying pre-tax profit at A$1.9m on A$27.8m of revenue. FY2026 then exposed the model's central weakness: the loss of one major OEM contract and the end of Austoyou cut revenue 15% to c. A$23.6m and pushed earnings to roughly breakeven, with the second half slightly loss-making.
What keeps the equity interesting is the balance sheet. With c. A$18m of cash and term deposits, negligible borrowings, owned land carried at A$6.05m and NTA of A$0.28 per share, the market is ascribing almost no value to the operating business. That discount is not irrational: returns on capital have been low even in good years, governance is concentrated in the founder and allied nominees, disclosure quality is uneven, and the company has a history of acquisitions that destroyed value. Nor is there a catalyst mechanism — no buyback, no broker coverage and very thin liquidity.
The investment debate therefore turns on two questions management has not yet answered publicly: can the newly commissioned Smithfield capacity be filled with diversified OEM work quickly enough to restore FY2025-level underlying profits, and will the board deploy its surplus cash in a way that benefits minority holders? Positive answers would make the stock look very cheap; negative ones would leave it a cash box with a low-return factory attached. On balance, this is a deep-value, high-governance-risk situation.
SOURCES CONSULTED
-
Star Combo Pharma Ltd, FY2025 Appendix 4E and Financial Report (26 Aug 2025) — announcements.asx.com.au/asxpdf/20250826/pdf/06nc6516rnd5tn.pdf
-
Star Combo Pharma Ltd, 1H FY2026 Appendix 4D (25 Feb 2026) — announcements.asx.com.au/asxpdf/20260225/pdf/06wr2zypg01lxk.pdf
-
Star Combo Pharma Ltd, 2023 Annual Report (27 Oct 2023) — announcements.asx.com.au/asxpdf/20231027/pdf/05wll45cd6mch7.pdf
-
Star Combo Pharma Ltd, 2024 Annual Report — investors.starcombo.com.au
-
Star Combo Pharma Ltd, 2022 Annual Report (28 Oct 2022) — announcements.asx.com.au/asxpdf/20221028/pdf/45gwjqny6ts9gg.pdf
-
Star Combo Pharma Ltd, FY2024 results release (20 Aug 2024); 1H FY2025 Appendix 4D (26 Feb 2025); 1H FY2024 Half Year Report; 2025 AGM CEO presentation (25 Nov 2025); Q2 FY22 Business Update
-
TipRanks stock analysis and revenue history; Yahoo Finance (S66.AX); Market Index; Morningstar Australia; Motley Fool Australia; InvestSMART (S66, float data); Simply Wall St; Google Finance; MarketScreener news feed
-
BDO deal note on Star Combo IPO; SmallCaps (Austoyou and Bio-E coverage); Pharmacy Daily (10 Jul 2019); Inside FMCG (10 May 2022)
-
Complementary Medicines Australia data via NutraIngredients (Feb 2025); Ken Research Australian supplements market reports; IBISWorld
-
IDN Financials, roic.ai and Canterbury Partners on the Pyridam–Probiotec transaction (2024)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Qualifications | Shareholding |
|---|---|---|---|---|---|
Richard Allely | Independent Non-executive Chairman | 2018 | Former MD & CEO of PMP Ltd (to 2012; CFO for seven years); senior roles at Tenix/Transfield, John Fairfax, Boral, James Hardie; prior boards include Perisher Blue, Australian Property Monitors, Source Financial Inc. | MBA (Finance), DipCM, FCPA, FAICD | Nil |
Jinxing (Star) Zhang | Managing Director (founder) | 2016 | Founded Star Combo in 2004; 10 years at a Chinese medical research company producing capsules, tablets and injections; pioneered hyaluronic-acid extraction/purification; director of Antoine International Pty Ltd | BSc (Biochemistry) | 38,165,510 shares (28.25%) |
Su Zhang | Chief Executive Officer and Executive Director | Joined company 2009 | Pharmacist; Terry White Chemists from 2006; Abbott Australia (Senior Drug Safety Associate, later APAC Regional Manager); responsible for quality, compliance, operations, production planning | MBA, Grad Cert Commerce, B.Pharm (University of Sydney) | 11,448,980 shares (8.48%) |
Jialong Ding | Non-executive Director (not independent in substance — represents Goldenmax International) | Not stated (on board by FY2023) | VP of pharmaceutical business at Goldenmax International; 30+ years in Chinese pharma distribution/production; ex-subsidiaries of Shanghai Pharma; former VP of China Nonprescription Medicines Association and Shanghai Pharmaceutical Profession Association | Senior Technician (Pharma Marketing & HR) | Nil |
Wei Han | Non-executive Director (Goldenmax International nominee) | Not stated (on board by FY2023) | Vice Chairman and director of Goldenmax International Technology Ltd; 30+ years in governance and accounting in Chinese food and consumer sectors | Professional statistician; listed-company board secretary | Nil |
Executive Leadership Team
| Name | Role | Since | Background |
|---|---|---|---|
Su Zhang | CEO | Exec since 2009 | See above |
James Ni | Chief Financial Officer (finance, tax, legal, IT) | 9 June 2022 | 20+ years in ASX-listed entities and accounting firms; IPO, M&A and integration experience; FCPA, CTA |
Patrick Raper | Company Secretary | Not stated | 25+ years as CFO/Company Secretary of ASX-listed entities; FCPA, FAICD |
Directors' Remuneration
| KMP | Salary/fees | Superannuation | Cash bonus | Equity | Total FY2025 | Total FY2024 |
|---|---|---|---|---|---|---|
Richard Allely (Chairman) | 91,324 | 10,502 | 0 | 0 | 101,826 | 101,370 |
Star Zhang (MD) | 183,452 | 21,097 | 0 | 0 | 204,549 | 199,827 |
Su Zhang (CEO) | 203,833 | 24,957 | 13,188 | 0 | 241,978 | 209,701 |
James Ni (CFO) | 166,149 | 19,813 | 6,143 | 0 | 192,105 | 182,044 |
Jialong Ding (NED) | 0 | 0 | 0 | 0 | 0 | 0 |
Wei Han (NED) | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 644,758 | 76,369 | 19,331 | 0 | 740,458 | 692,942 |
Major Shareholders
| Holder | Shares | % of issued capital | Source |
|---|---|---|---|
Jinxing (Star) Zhang | 38,165,510 | 28.25 | Market Index (15 Oct 2025) |
Su Zhang | 11,448,980 | 8.48 | FY2025 Remuneration Report |
Other top-10 holders | Not publicly disclosed in sources reviewed (see ASX Additional Information section of the annual report) | — | — |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Ownership / status | Relative positioning vs Star Combo |
|---|---|---|---|
Probiotec Ltd | Contract manufacturing of OTC, complementary medicines, powders, liquids; packing | Acquired by PT Pyridam Farma (Indonesia) June 2024 for c. A$251m equity (EV c. A$325m); delisted | Far larger (six Australian facilities); broader dosage forms; now foreign-owned |
Lipa Pharmaceuticals | Complementary-medicine contract manufacturing (NSW) | Private | Larger-scale direct OEM rival |
Vitex Pharmaceuticals | Contract manufacturing (NSW) | Private | Direct OEM rival |
Catalent (Australian operations) | Softgel/contract manufacturing | Part of Catalent Inc. (acquired by Novo Holdings, 2024) | Global scale; different dosage-form focus |
Nature's Care Manufacture | Supplements, contract manufacturing | Private | Integrated brand-plus-manufacturer; China export focus |
Blackmores | Branded vitamins (own manufacturing at Braeside, VIC) | Acquired by Kirin Holdings (2023); delisted | Category leader; competes with own brands and absorbs volume in-house |
H&H Group (Swisse) | Branded supplements | HKEX: 1112 | Major brand owner; outsources manufacturing — potential customer as well as competitor |
Vitaco (Healtheries, Musashi, Nutra-Life) | Branded supplements and manufacturing (NZ/AU) | Owned by By-health (China) | Integrated competitor |
Asian contract manufacturers (China, Vietnam, Thailand) | Low-cost OEM for Asian markets | Various | Price competitors for export-market OEM, but lack "Made in Australia"/TGA credentials |
Australian Natural Therapeutics / other small TGA-licensed OEMs | OEM | Private | Peer-sized competitors |
Peer Comparison FY2026
| Metric | Star Combo FY2025 | Star Combo FY2026 |
|---|---|---|
Revenue | A$27.8m | A$23.6m |
Revenue growth | 6.9% | -15.2% |
Gross margin | 22.6% | 21.2% |



